OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial
Paula Ghaneh, Daniel H. Palmer, Silvia Cicconi, et al.
The Lancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 2, pp. 157-168
Open Access | Times Cited: 187
Paula Ghaneh, Daniel H. Palmer, Silvia Cicconi, et al.
The Lancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 2, pp. 157-168
Open Access | Times Cited: 187
Showing 1-25 of 187 citing articles:
Neoadjuvant therapy for pancreatic cancer
Christoph Springfeld, Cristina R. Ferrone, Matthew H. G. Katz, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 5, pp. 318-337
Closed Access | Times Cited: 205
Christoph Springfeld, Cristina R. Ferrone, Matthew H. G. Katz, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 5, pp. 318-337
Closed Access | Times Cited: 205
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Thierry Conroy, Per Pfeiffer, Valérie Vilgrain, et al.
Annals of Oncology (2023) Vol. 34, Iss. 11, pp. 987-1002
Open Access | Times Cited: 174
Thierry Conroy, Per Pfeiffer, Valérie Vilgrain, et al.
Annals of Oncology (2023) Vol. 34, Iss. 11, pp. 987-1002
Open Access | Times Cited: 174
Therapeutic developments in pancreatic cancer
Zilun Hu, Eileen M. O’Reilly
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 7-24
Closed Access | Times Cited: 123
Zilun Hu, Eileen M. O’Reilly
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 7-24
Closed Access | Times Cited: 123
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial
Knut Jørgen Labori, Svein Olav Bratlie, Bodil Andersson, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 3, pp. 205-217
Closed Access | Times Cited: 85
Knut Jørgen Labori, Svein Olav Bratlie, Bodil Andersson, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 3, pp. 205-217
Closed Access | Times Cited: 85
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer
Thomas F. Stoop, Rutger T. Theijse, Leonard W. F. Seelen, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 2, pp. 101-124
Closed Access | Times Cited: 60
Thomas F. Stoop, Rutger T. Theijse, Leonard W. F. Seelen, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 2, pp. 101-124
Closed Access | Times Cited: 60
FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review
Dilmurodjon Eshmuminov, Botirjon Aminjonov, Russell F. Palm, et al.
Annals of Surgical Oncology (2023) Vol. 30, Iss. 7, pp. 4417-4428
Open Access | Times Cited: 41
Dilmurodjon Eshmuminov, Botirjon Aminjonov, Russell F. Palm, et al.
Annals of Surgical Oncology (2023) Vol. 30, Iss. 7, pp. 4417-4428
Open Access | Times Cited: 41
Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas
Leila T. Tchelebi, Diana Segovia, Koren Smith, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 120, Iss. 1, pp. 111-119
Closed Access | Times Cited: 29
Leila T. Tchelebi, Diana Segovia, Koren Smith, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 120, Iss. 1, pp. 111-119
Closed Access | Times Cited: 29
Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreatic Cancer
Won‐Gun Yun, Yoon Soo Chae, Youngmin Han, et al.
Annals of Surgical Oncology (2025) Vol. 32, Iss. 4, pp. 2819-2829
Open Access | Times Cited: 2
Won‐Gun Yun, Yoon Soo Chae, Youngmin Han, et al.
Annals of Surgical Oncology (2025) Vol. 32, Iss. 4, pp. 2819-2829
Open Access | Times Cited: 2
Advances in the management of pancreatic cancer
Marco Del Chiaro, Toshitaka Sugawara, Sana D. Karam, et al.
BMJ (2023), pp. e073995-e073995
Open Access | Times Cited: 36
Marco Del Chiaro, Toshitaka Sugawara, Sana D. Karam, et al.
BMJ (2023), pp. e073995-e073995
Open Access | Times Cited: 36
Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
Heng‐Chung Kung, Jun Yu
MedComm (2023) Vol. 4, Iss. 2
Open Access | Times Cited: 24
Heng‐Chung Kung, Jun Yu
MedComm (2023) Vol. 4, Iss. 2
Open Access | Times Cited: 24
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective cohort study
Zheng Li, Qifeng Zhuo, Borui Li, et al.
World Journal of Surgical Oncology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Zheng Li, Qifeng Zhuo, Borui Li, et al.
World Journal of Surgical Oncology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Anatomical and Biological Considerations to Determine Resectability in Pancreatic Cancer
Ingmar F. Rompen, Joseph R. Habib, Christopher L. Wolfgang, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 489-489
Open Access | Times Cited: 8
Ingmar F. Rompen, Joseph R. Habib, Christopher L. Wolfgang, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 489-489
Open Access | Times Cited: 8
Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter TONO Study
Pietro Addeo, Milena Muzzolini, Christophe Laurent, et al.
Annals of Surgical Oncology (2025)
Closed Access | Times Cited: 1
Pietro Addeo, Milena Muzzolini, Christophe Laurent, et al.
Annals of Surgical Oncology (2025)
Closed Access | Times Cited: 1
Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control
Shannon Nicole Russell, Constantinos Demetriou, Giampiero Valenzano, et al.
Gut (2025), pp. gutjnl-333492
Closed Access | Times Cited: 1
Shannon Nicole Russell, Constantinos Demetriou, Giampiero Valenzano, et al.
Gut (2025), pp. gutjnl-333492
Closed Access | Times Cited: 1
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
ASO Author Reflections: Complete Pathological Response after Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinomas—Curative Surgery in Cured Patients?
Pietro Addeo, Milena Muzzolini, Christophe Laurent, et al.
Annals of Surgical Oncology (2025) Vol. 32, Iss. 4, pp. 2861-2863
Closed Access | Times Cited: 1
Pietro Addeo, Milena Muzzolini, Christophe Laurent, et al.
Annals of Surgical Oncology (2025) Vol. 32, Iss. 4, pp. 2861-2863
Closed Access | Times Cited: 1
Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response
Rong Tang, Jin Xu, Wei Wang, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 10, pp. 101234-101234
Open Access | Times Cited: 19
Rong Tang, Jin Xu, Wei Wang, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 10, pp. 101234-101234
Open Access | Times Cited: 19
Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer
Casper W.F. van Eijck, Dana A. M. Mustafa, Disha Vadgama, et al.
Gut (2023) Vol. 73, Iss. 2, pp. 311-324
Open Access | Times Cited: 18
Casper W.F. van Eijck, Dana A. M. Mustafa, Disha Vadgama, et al.
Gut (2023) Vol. 73, Iss. 2, pp. 311-324
Open Access | Times Cited: 18
Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma
Maciej Słodkowski, Marek Wroński, Dominika Karkocha, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2584-2584
Open Access | Times Cited: 16
Maciej Słodkowski, Marek Wroński, Dominika Karkocha, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2584-2584
Open Access | Times Cited: 16
New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy
Sofia Dallavalle, Gabriele Campagnoli, Paola Pastena, et al.
Medicina (2024) Vol. 60, Iss. 7, pp. 1070-1070
Open Access | Times Cited: 6
Sofia Dallavalle, Gabriele Campagnoli, Paola Pastena, et al.
Medicina (2024) Vol. 60, Iss. 7, pp. 1070-1070
Open Access | Times Cited: 6
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Daniel H. Palmer, Richard Jackson, Christoph Springfeld, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 6
Daniel H. Palmer, Richard Jackson, Christoph Springfeld, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 6
Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment
Kenji Ikezawa, Makiko Urabe, Yugo Kai, et al.
Japanese Journal of Clinical Oncology (2023) Vol. 54, Iss. 3, pp. 271-281
Open Access | Times Cited: 13
Kenji Ikezawa, Makiko Urabe, Yugo Kai, et al.
Japanese Journal of Clinical Oncology (2023) Vol. 54, Iss. 3, pp. 271-281
Open Access | Times Cited: 13
Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2)
Ingvild Farnes, Dyre Kleive, Caroline S. Verbeke, et al.
BJS Open (2023) Vol. 7, Iss. 6
Open Access | Times Cited: 13
Ingvild Farnes, Dyre Kleive, Caroline S. Verbeke, et al.
BJS Open (2023) Vol. 7, Iss. 6
Open Access | Times Cited: 13
Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer
Mengyuan Liu, Alice C. Wei
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 3, pp. 629-642
Closed Access | Times Cited: 5
Mengyuan Liu, Alice C. Wei
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 3, pp. 629-642
Closed Access | Times Cited: 5
